Loading...
Loading...
NTRB| Name | Value |
|---|---|
| Revenues | 442.8K |
| Cost of Revenue | 352.0K |
| Gross Profit | 90.8K |
| Operating Expense | 1,500.6K |
| Operating I/L | -1,409.7K |
| Other Income/Expense | -295.7K |
| Interest Income | 77.3K |
| Pretax | -1,705.5K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,705.5K |
Nutriband Inc. develops a range of transdermal pharmaceutical products, including AVERSA fentanyl, an extended-release transdermal fentanyl system for chronic pain management. The company also offers AVERSA buprenorphine, AVERSA methylphenidate, exenatide for type 2 diabetes, and follicle stimulating hormone for infertility. Additionally, Nutriband Inc. has a license agreement for the development of the RAMBAM Closed System Transfer Devices. The company generates revenue through the sale of its transdermal pharmaceutical products and through licensing agreements for its medical devices.
